Press Releases
Press Releases
-
Rezolute to Participate in Upcoming Investor Conferences in March
-
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
-
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
-
Rezolute Announces Change of Transfer Agent
-
FDA Clears Rezolute’s IND Application for RZ402
-
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Rezolute Announces Uplisting to the Nasdaq Capital Market
-
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
-
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
-
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
